Vitamin C ( DrugBank: Vitamin C )


6 diseases
告示番号疾患名(ページ内リンク)臨床試験数
10シャルコー・マリー・トゥース病1
192コケイン症候群1
206脆弱X症候群3
210単心室症1
211左心低形成症候群1
212三尖弁閉鎖症1

10. シャルコー・マリー・トゥース病


臨床試験数 : 39 薬物数 : 44 - (DrugBank : 9) / 標的遺伝子数 : 11 - 標的パスウェイ数 : 15
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00484510
(ClinicalTrials.gov)
April 20078/6/2007High Dose Ascorbic Acid Treatment of CMT1AA Randomized, Placebo-controlled, Double Masked 120 Subject Futility Design Clinical Trial of Ascorbic Acid Treatment of Charcot Marie Tooth Disease Type 1A.Charcot-Marie-Tooth Disease, Type IaDrug: Ascorbic acid (Vitamin C);Drug: placeboWayne State UniversityMuscular Dystrophy Association;Charcot-Marie-Tooth AssociationCompleted13 Years70 YearsBoth110Phase 2/Phase 3United States

192. コケイン症候群


臨床試験数 : 4 薬物数 : 7 - (DrugBank : 3) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 51
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR1900026719
2019-11-012019-10-19Clinical study for combined application of vitamin C and quercetin in the treatment of Cockayne's syndromeClinical study for combined application of vitamin C and quercetin in the treatment of Cockayne's syndrome Cockayne's syndrometest group:Vitamin C and Quercetin;The First Medical Center of PLA General HospitalNULLPending613Bothtest group:20;China

206. 脆弱X症候群


臨床試験数 : 104 薬物数 : 87 - (DrugBank : 32) / 標的遺伝子数 : 54 - 標的パスウェイ数 : 79
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-005460-42-ES
(EUCTR)
07/07/201620/04/2016Clinical trial to evaluate ascorbic acid (vitamin C) and tocopherol (vitamin E) in combination versus placebo for the treatment of cognitive and behavioral disorders in children with fragile x syndromePhase III clinical trial, double-blind, cross-way, to evaluate the safety and efficacy ascorbic acid (vitamin C) and tocopherol (vitamin E) combination versus placebo for the treatment of cognitive and behavioral disorders in children with fragile x syndrome Fragile x syndrome
MedDRA version: 19.0;Level: PT;Classification code 10017324;Term: Fragile X syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Vitamin C
INN or Proposed INN: Vitamin C
Other descriptive name: ACIDUM ASCORBICUM D6
Product Name: Vitamin E
INN or Proposed INN: Vitamin E
Other descriptive name: TOCOPHERYL ACETATE
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y SaludNULLNot RecruitingFemale: no
Male: yes
Phase 3Spain
2NCT02942498
(ClinicalTrials.gov)
July 20167/10/2016Clinical Trial for Asses the Safety and Efficacy of Vitamin C and Vitamin E in Combination Versus Placebo for Treating Cognitive and Behavior Disorder in Children With Fragile X SyndromeClinical Trials Phase III, Double Blind, Crossover to Asses the Safety and Efficacy of Vitamin C and Vitamin E in Combination Versus Placebo for Treating Cognitive and Behavior Disorder in Children With Fragile X SyndromeX Fragile SyndromeDrug: Vitamin C 10mg/Kg Vitamin E 10 mg/Kg;Drug: PlaceboFundación Pública Andaluza para la Investigación de Málaga en Biomedicina y SaludDelos ClinicalRecruiting1 Year8 YearsBoth40Phase 3Spain
3NCT01329770
(ClinicalTrials.gov)
December 201029/3/2011Safety and Efficacy Study of Antioxidants for the Treatment of the Fragile X SyndromePhase II Double-blind Randomized Placebo-controlled 1-way Crossover Trial to Investigate Safety and Efficacy of the Ascorbic Acid and Tocopherol for the Treatment of the Fragile X SyndromeFragile X SyndromeDietary Supplement: Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E);Dietary Supplement: PlaceboYolanda de Diego OteroNULLCompleted6 Years18 YearsMale30Phase 2Spain

210. 単心室症


臨床試験数 : 49 薬物数 : 53 - (DrugBank : 23) / 標的遺伝子数 : 32 - 標的パスウェイ数 : 67
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00974025
(ClinicalTrials.gov)
June 20099/9/2009Impact of Vitamin C on Endothelial Function and Exercise Capacity in Fontan-Palliated PatientsVitamin C May Improve Endothelial Function and Exercise Capacity in Functional Single Ventricle Patients After Fontan PalliationFontan Procedure;Hypoplastic Left Heart Syndrome;Tricuspid AtresiaDietary Supplement: Vitamin C;Dietary Supplement: PlaceboUniversity of MichiganGriese-Hutchinson Champions for Children's Hearts Investigator AwardCompleted8 Years25 YearsAll53N/AUnited States

211. 左心低形成症候群


臨床試験数 : 21 薬物数 : 29 - (DrugBank : 9) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 14
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00974025
(ClinicalTrials.gov)
June 20099/9/2009Impact of Vitamin C on Endothelial Function and Exercise Capacity in Fontan-Palliated PatientsVitamin C May Improve Endothelial Function and Exercise Capacity in Functional Single Ventricle Patients After Fontan PalliationFontan Procedure;Hypoplastic Left Heart Syndrome;Tricuspid AtresiaDietary Supplement: Vitamin C;Dietary Supplement: PlaceboUniversity of MichiganGriese-Hutchinson Champions for Children's Hearts Investigator AwardCompleted8 Years25 YearsAll53N/AUnited States

212. 三尖弁閉鎖症


臨床試験数 : 6 薬物数 : 8 - (DrugBank : 7) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 12
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00974025
(ClinicalTrials.gov)
June 20099/9/2009Impact of Vitamin C on Endothelial Function and Exercise Capacity in Fontan-Palliated PatientsVitamin C May Improve Endothelial Function and Exercise Capacity in Functional Single Ventricle Patients After Fontan PalliationFontan Procedure;Hypoplastic Left Heart Syndrome;Tricuspid AtresiaDietary Supplement: Vitamin C;Dietary Supplement: PlaceboUniversity of MichiganGriese-Hutchinson Champions for Children's Hearts Investigator AwardCompleted8 Years25 YearsAll53N/AUnited States